Attached files
Exhibit 99.3
MEDITE Cancer Diagnostics Announces Reorganization of Germany
Operations
Orlando,
FL, May 10th, 2017 – MEDITE Cancer Diagnostics, Inc. (OTCQB:
MDIT) (the “Company”) specializing in the development,
manufacturing and marketing of molecular biomarkers and premium
medical devices for detection, risk assessment and diagnosis of
cancer and precancerous conditions, announces further restructuring
of its organization in Germany to position the Company for revenue
growth and profitability.
On May
4, 2017, the Board of Directors (the “Board”) of MEDITE
Cancer Diagnostics, Inc. (the “Company”) accepted the
resignation of Michaela Ott as Chief Operating Officer of the
Company, effective immediately. Further, the Board accepted Ms.
Ott’s resignation from her position as Managing Director of
the Company’s wholly-owned subsidiary, Medite GmbH, as well
as managing director of CytoGlobe GmbH, Burgdorf, a wholly owned
subsidiary of Medite GmbH, effective immediately. Ms. Ott shall
further resign from her position as Managing Director of Medite
GmbH, Austria, also a wholly-owned subsidiary of Medite GmbH,
effective no later than September 30, 2017. Michaela Ott will
remain on the Board of Directors.
Further,
on May 4, 2017, the Board also accepted the resignation of Michael
Ott as Chairman of the Board, effective immediately. Mr. Ott shall
remain on the Board of Directors of the Company. Mr. Ott further
resigned as Managing Director of the Company’s wholly-owned
German subsidiary, Medite GmbH, as well as from his position as
Managing Director of CytoGlobe GmbH, Burgdorf, a wholly-owned
subsidiary of Medite GmbH, effective immediately. Mr. Ott shall
resign from his position as Managing Director of Medite sp. z.
o.o., Poland, also a wholly-owned subsidiary of Medite GmbH,
effective no later than September 30, 2017
On May
4, 2017, the Board thereafter, by unanimous consent, appointed
Stephen Von Rump to the position of Chief Commercialization and
Strategy Officer of the Company to serve until such time as his
removal or resignation. Mr. Von Rump was further appointed to the
position of Managing Director of Medite GmbH, until such time as
his resignation or termination.
On May
4, 2017, the Board unanimously elected David E. Patterson, the
Company’s Chief Executive Officer and Director, to the
position of Chairman of the Board of Directors of the Company, to
serve until his resignation or removal.
The
three new reporting lines as previously stated have been
implemented into the organization in Germany. All sales,
marketing and sales fulfillment personnel and activities will
report into Jeff Rencher, Chief Marketing and Business Development
Officer. All manufacturing, R&D, technical service and
quality management personnel and activities will report into
Stephen Von Rump, Chief Commercialization and Strategy
Officer. All financial personnel and activities will report
into Susan Weisman, Chief Financial Officer.
Mr.
Rencher, Mr. Von Rump and Ms. Weisman all report directly to David
Patterson, Chief Executive Officer of the Company.
“This
new organization is executing plans to increase MEDITE’s
market presence short term within the core business, commercialize
new offerings from MEDITE’s R&D teams in the U.S. and
Germany, and ensure the launch of new products in China in
2017,” said Mr. Patterson. “These actions allow MEDITE
to gain a secure financial footing and realize its charter as a
leading provider of cancer diagnostic products.”
About MEDITE Cancer Diagnostics, Inc.
MEDITE
Cancer Diagnostics Inc., is a Delaware registered company
consisting of wholly-own MEDITE GmbH a Germany-based company with
its subsidiaries. On April 3, 2014, MEDITE was acquired by former
CytoCore, Inc. a biomolecular diagnostics company engaged in the
design, development, and commercialization of cost-effective cancer
screening systems and Biomarkers to assist in the early detection
of cancer. By acquiring MEDITE the company changed from solely
research operations to an operating company with a well-developed
infrastructure, 80 employees in four countries, a distribution
network to about 70 countries worldwide, a well-known and
established brand name and a wide range of products for anatomic
pathology, histology and cytology laboratories.
Forward Looking Statement
This press release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
regarding future operating performance, events, trends and plans.
All statements other than statements of historical fact contained
herein, including, without limitation, statements regarding our
future financial position, business strategy, budgets, projected
revenues and costs, and plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements generally can be identified by the use of
forward-looking terminology such as “may,”
“will,” “expects,” “intends,”
“plans,” “projects,”
“estimates,” “anticipates,” or
“believes” or the negative thereof or any variation
thereon or similar terminology or expressions. We have based these
forward-looking statements on our current expectations and
projections about future events. These forward-looking statements
are not guarantees and are subject to known and unknown risks,
uncertainties and assumptions about us that may cause our actual
results, levels of activity, performance or achievements to be
materially different from any future results, levels of activity,
performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause our
actual results to differ from our expectations, include but are not
limited to, MEDITE’s ability to maintain and grow its
revenues. Readers are cautioned not to place undue reliance on our
forward-looking statements, as they speak only as of the date made.
Such statements are not guarantees of future performance or events
and we undertake no obligation to disclose any revision to these
forward-looking statements to reflect events or circumstances
occurring after the date hereof.
For more information please visit: www.medite-group.com
Investor Contact:
David Patterson CEO
317-341-3589